The Recent National Lipid Association Recommendations: How Do They Compare to Other Established Dyslipidemia Guidelines?

Current Atherosclerosis Reports

Volumn 17, Issue 4, 2015, Pages

  Flink, Laura ^a   Underberg, James A ^b   Newman, Jonathan D ^a   Gianos, Eugenia ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atherosclerotic cardiovascular disease risk; Cholesterol treatment; Dyslipidemia; International Atherosclerosis Society; Lipid guidelines; National Lipid Association; Risk calculator; The American Association of Clinical Endocrinologists; The American College of Cardiology American Heart Association

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; CHOLESTEROL DERIVATIVE; CREATININE; ENZYME INHIBITOR; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MONOUNSATURATED FATTY ACID; NICOTINIC ACID; OMEGA 3 FATTY ACID; PITAVASTATIN; POLYUNSATURATED FATTY ACID; PRAVASTATIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

AGE; APHERESIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY CALCIUM SCORE; CORONARY ARTERY DISEASE; DIETITIAN; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOCRINOLOGIST; EXERCISE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; FOLLOW UP; FOOD INTAKE; FRAMINGHAM RISK SCORE; HIGH RISK PATIENT; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPODYSTROPHY; LOW FAT DIET; OBESITY; PATHOGENESIS; PATIENT MONITORING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIMARY PREVENTION; RED MEAT; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING; SMOKING CESSATION; SODIUM RESTRICTION; TREATMENT RESPONSE; VEGETABLE; WEIGHT REDUCTION; COMPARATIVE STUDY; DISEASE MANAGEMENT; DYSLIPIDEMIAS; MEDICAL SOCIETY; PATIENT CARE PLANNING;

ANTICHOLESTEREMIC AGENTS; DISEASE MANAGEMENT; DYSLIPIDEMIAS; FATTY ACIDS, OMEGA-3; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NIACIN; PATIENT CARE PLANNING; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK REDUCTION BEHAVIOR; SOCIETIES, MEDICAL;

EID: 84922998626     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-015-0494-9     Document Type: Review

References (16)

1. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88. The NLA recommendation document is the most recent of the recommendations to be released and is used in our paper to compare other established guidelines.
2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.
3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421.
4. D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.
5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. The 2013 ACC/AHA guideline on the treatment of blood cholesterol is one of the major guidelines reviewed in our paper.
6. http://www.cardiosource.org/science-andquality/hmaoca,practice-guidelines-and-quality-standards/2013-prevention-guideline-tools.aspx.
7. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8.
8. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.
9. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302–9.
10. Grundy SM. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561–5.
11. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol 2014;8(1):29-60. The International Atherosclerosis Society global recommendations for the management of dyslipidemia document is one of the major guidelines reviewed in our paper.
12. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9.
13. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51. 4p following 2251.
14. Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1–78. The American association of clinical endocrinologists’ guidelines for management of dyslipidemia document is one of the major guidelines reviewed in our paper.
15. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation. 2012;125(14):1748–56. 14.
16. Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960–84.